FilingSEC EDGAR8-K
Corbus Pharmaceuticals Announces Positive Topline Data from Phase 1b Trial of CRB-913
· SEC accepted
StagePhase 1b
Filing content
The company reported positive topline data from the Phase 1b trial of CRB-913, showing 5% weight loss at 12 weeks with a favorable safety profile. It plans to initiate a Phase 2 study in 1H 2027.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…